Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice (original) (raw)
Thrombosis and Haemostasis
AI-generated Abstract
Apixaban, a direct oral anticoagulant, has shown to be effective in managing venous thromboembolism (VTE) compared to warfarin in a real-world setting. In a large observational study, patients receiving apixaban had significantly lower risks of VTE recurrences and major bleeding events compared to those treated with warfarin. The increasing utilization of apixaban raises concerns regarding its prescription in patients with conditions typically excluded from pivotal trials, necessitating further real-world evidence to evaluate its safety and effectiveness.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.